Kenneth S. Abramowitz, co-founder and Managing General Partner of NGN Capital. See sector focus and contact routes.
Kenneth S. Abramowitz, co-founder and Managing General Partner of NGN Capital, invests primarily in **late-stage** healthcare and biotechnology ventures, including pharmaceuticals (Phase II clinical trials), medical devices (pre- or post-FDA approval), and healthcare services [1][5]. His firm typically deploys **checks up to $10 million** per investment, with a portfolio wholly concentrated in life sciences [1][3]. Notable portfolio companies include **Sightline Technologies** (sold to Stryker Corp. for $150 million), **Small Bone Innovations** (Series B co-lead), and board seats at **BeneChill**, **Mitraltech**, **Cerapedics**, and **Akorn** [1][2][7]. Abramowitz’s distinctive thesis emphasizes **US and Europe-focused**, later-stage healthcare companies poised for regulatory milestones or commercialization [1][5][10].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Lake Worth when building a target list.
Investors like Kenneth S. Abramowitz · Full investor directory · Investor access · Company funding database